PAVmed (PAVM) Prices 9.8M Share Common Offering for Gross Proceeds of Approx. $45M

After-Hours Stock Movers 02/22: (EVER) (ZI) (FIVN) Higher; (PAVM) (NLS) (GDOT) Lower (more...)

Today's After-Hours Stock Movers

PAVmed Inc. (Nasdaq: PAVM) 12.4% LOWER; announced that it is commencing an underwritten public offering of its common stock. PAVmed also expects to grant to the underwriter for the Offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering

EverQuote (NASDAQ: EVER) 12.3% HIGHER; reported Q4 EPS of ($0.13), $0.02 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $97.3 million versus the consensus estimate of... More

PAVmed (PAVM) to Offer Common Stock

PAVmed Inc. (Nasdaq: PAVM) announced that it is commencing an underwritten public offering of its common stock. PAVmed also expects to grant to the underwriter for the Offering a 30-day option to purchase up to an additional 15% of the number of shares of... More

PAVmed (PAVM) majority-owned subsidiary Lucid Diagnostics to spin-off into separate public company

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the Company or PAVmed), a highly differentiated, multi-product, commercial-stage medical device company, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (Lucid) and Solys Diagnostics Inc. (Solys), discussed preliminary financial results for the three and 12 months ended December 31, 2020 and made two strategic announcements regarding Lucid and its EsoGuard® product.

Following a strong fourth quarter of 2020 and start of 2021, including raising over $30 million from institutional investors, we find ourselves in the strongest financial position in our history and with the confidence and determination necessary to rapidly and effectively advance and... More